Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results
December 5, 2020 6:00 pmOne patient had a complete response and the majority of patients achieved disease control at 12 weeks.
A phase 1 trial of an anti-folate receptor alpha (FolRα) human immunoglobulin G1 (IgG1) antibody for women with advanced ovarian cancer showed responses